Floatz logo

Rucaparib

Recurrent Large Cell Lung Carcinoma

SWOG Cancer Research NetworkSmall moleculePhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Recurrent Large Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 4A
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Vinorelbine
AIO-Studien-gGmbH
Phase 3BB
Gefetinib
National Cancer Institute (NCI)
Phase 3BB

View all 34 →

Same molecule, other indications

Rucaparib is also rated in:

peritoneum cancerDormant
BB
Indicative ·
66 / 100
View asset →
Metastatic Castration Resistant Prostate CancerDormant
BB
Indicative ·
64 / 100
View asset →
ovarian cancerDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →